|Assessment process complete
|For the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Assessment Recommended
|Full pharmacoeconomic assessment commissioned by HSE
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not recommended at the submitted price
The HSE has approved reimbursement following confidential price negotiations.